A novel series consisting of eight imidazol-pyrazole hybrids ( 9a-h) are synthesized using a base catalyzed one pot multi-component reaction (MCR) and screened for in vitro biological activities. All compounds were found to display high biological activities but compound 9g was found to be the most active against EGFR (IC50 of 0.11 ± 0.02 μm), A549 and HepG2, while compound 9h was found to be most active against FabH (IC50 of 2.6 μm) E. coli. The DFT studies and molecular docking was done for compounds 9a-h to calculate the distance and angle between the active parts of the molecules and charge density over the molecules affecting the binding of molecules in the active pockets with greater binding affinity.
In this work, a new series of imidazole-pyrazole-benzo[f]chromene hybrids were designed and synthesized by a base-catalyzed cyclo-condensation through a one-pot multicomponent reaction. All compounds were tested for in vitro antimicrobial and anticancer activities. Enzyme inhibitory activities of all compounds were carried out against FabH and EGFR. The majority of synthesized compounds displayed promising antimicrobial as well as anticancer activity against used strains and cancer cell lines respectively. The compounds were also tested for in vitro anticancer activities against two cancer cell lines A549 and Hep G2. Compound 7f (IC50 = 0.62 µM) against EGFR and (IC50 = 1.31 µM) against A549 kinase displayed the most potent inhibitory activity as compared to another member of the series. In the molecular modelling study, compound 7e was bound into the active pocket of EGFR with one pi-pi interaction and one hydrogen bond having minimum binding energy ∆Gb = −7.6894 kcal/mol. Moreover, FabH molecule 7d was found to be binding in the active pocket with a minimum binding energy of −8.9117 kcal/mol.